Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319042 | 1.00 | CES2 (0.52) | CES2MAPK1CYP1A2TP53TSHR | |
| SCHEMBL9632303 | 1.00 | CES2 (0.52) | CES2MAPK1CYP1A2TP53TSHR | |
| SCHEMBL200399 | 1.00 | CES2 (0.52) | CES2MAPK1CYP1A2TP53TSHR | |
| SCHEMBL198090 | 1.00 | CES2 (0.52) | CES2MAPK1CYP1A2TP53TSHR | |
| SCHEMBL200766 | 1.00 | CES2 (0.52) | CES2MAPK1CYP1A2TP53TSHR | |
| Iodide SCHEMBL9630545 | 0.98 | CES2 (0.50) | CES2MAPK1CYP1A2TP53TSHR | |
| Hydrochloric Acid SCHEMBL7561213 | 0.98 | CES2 (0.50) | CES2MAPK1CYP1A2TP53TSHR | |
| Hydrochloric Acid SCHEMBL16990768 | 0.98 | CES2 (0.50) | CES2MAPK1CYP1A2TP53TSHR | |
| Hydrochloric Acid SCHEMBL9632302 | 0.98 | CES2 (0.50) | CES2MAPK1CYP1A2TP53TSHR | |
| Iodide SCHEMBL9630733 | 0.98 | CES2 (0.50) | CES2MAPK1CYP1A2TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250336540-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-30 | — | — | US | claimed |
| US-12292445-B2 | Methods of selecting subjects for treatment with metabolomic modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-06 | — | — | US | claimed |
| EP-4515242-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN Pharmaceutica NV (BE) | 2025-03-05 | — | — | EP | claimed |
| WO-2023209218-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-02 | — | — | WO | claimed |
| US-20210407677-A1 | FATTY ACID AND KREBS CYCLE METABOLOMIC MEASURES FOR TREATMENT OF HEAD INJURY | NORTHWESTERN UNIVERSITY (US) | 2021-12-30 | — | — | US | claimed |
| US-20210364526-A1 | METHODS OF SELECTING SUBJECTS FOR TREATMENT WITH METABOLOMIC MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-25 | — | — | US | claimed |
| EP-0707489-A4 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS INC (US) | 1998-07-29 | — | — | EP | claimed |
| EP-0707489-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | Scotgen Biopharmaceuticals, Inc. (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1994025053-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS, INC. (US) | 1994-11-10 | — | — | WO | claimed |
| EP-0206947-B1 | PHARMACEUTICAL COMPOSITION CONTAINING CHOLINE ESTER SALTS FOR ENHANCING GASTROINTESTINAL TRACT ABSORPTION | MERCK & CO. INC. (US) | 1992-04-15 | — | — | EP | claimed |
| EP-0214898-B1 | CHOLINE ESTERS AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL CAVITIES | MERCK & CO. INC. (US) | 1992-03-11 | — | — | EP | claimed |
| US-4973579-A | VIRICIDES | MERCK & CO., INC. (US) | 1990-11-27 | — | — | US | claimed |
| US-4963556-A | ANTIVIRAL AGENTS | MERCK & CO., INC. (US) | 1990-10-16 | — | — | US | claimed |
| US-4835138-A | Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities | MERCK & CO., INC. (US) | 1989-05-30 | — | — | US | claimed |
| US-4822773-A | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts | MERCK & CO., INC. (US) | 1989-04-18 | — | — | US | claimed |
| US-4729989-A | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts | MERCK & CO., INC. (US) | 1988-03-08 | — | — | US | claimed |
| US-4692441-A | B-LACTAM ANTIBIOTICS | MERCK & CO., INC. (US) | 1987-09-08 | — | — | US | claimed |
| EP-0214898-A2 | Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities | MERCK & CO. INC. (US) | 1987-03-18 | — | — | EP | claimed |
| EP-0206947-A2 | Pharmaceutical composition containing choline ester salts for enhancing gastrointestinal tract absorption | MERCK & CO. INC. (US) | 1986-12-30 | — | — | EP | claimed |
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | UNIV CALIFORNIA (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250336540-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-30 | — | — | US | disclosed |
| US-12292445-B2 | Methods of selecting subjects for treatment with metabolomic modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-06 | — | — | US | disclosed |
| EP-4515242-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN Pharmaceutica NV (BE) | 2025-03-05 | — | — | EP | disclosed |
| US-20240257973-A1 | DISEASE SPECTRUM CLASSIFICATION | PATIENTSLIKEME LLC (US) | 2024-08-01 | — | — | US | disclosed |
| US-11894139-B1 | Disease spectrum classification | PATIENTSLIKEME LLC (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230404957-A1 | Pet Food Compositions | HILL'S PET NUTRITION, INC. (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230371552-A1 | Pet Food Compositions | HILL'S PET NUTRITION, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2023209218-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-02 | — | — | WO | disclosed |
| EP-3419753-B1 | QUATERNARY AMMONIUM SULFUR-CONTAINING BINUCLEAR MOLYBDATE SALTS AS LUBRICANT ADDITIVES | VANDERBILT CHEMICALS LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20220102000-A1 | PREDICTING BLOOD METABOLITES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-03-31 | — | — | US | disclosed |
| CN-110478331-B | Drug-loaded bacteria outer membrane vesicle and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2022-02-18 | — | — | CN | disclosed |
| US-20210407677-A1 | FATTY ACID AND KREBS CYCLE METABOLOMIC MEASURES FOR TREATMENT OF HEAD INJURY | NORTHWESTERN UNIVERSITY (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210364526-A1 | METHODS OF SELECTING SUBJECTS FOR TREATMENT WITH METABOLOMIC MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-25 | — | — | US | disclosed |
| US-10590364-B2 | Quaternary ammonium sulfur-containing binuclear molybdate salts as lubricant additives | VANDERBILT CHEMICALS, LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190310269-A1 | SYSTEMS AND METHODS FOR MEASURING OBESITY USING METABOLOME ANALYSIS | HUMAN LONGEVITY, INC. | 2019-10-10 | — | — | US | disclosed |
| EP-3419753-A1 | QUATERNARY AMMONIUM SULFUR-CONTAINING BINUCLEAR MOLYBDATE SALTS AS LUBRICANT ADDITIVES | Vanderbilt Chemicals, LLC (US) | 2019-01-02 | — | — | EP | disclosed |
| US-20180327685-A1 | Quaternary Ammonium Sulfur-Containing Binuclear Molybdate Salts as Lubricant Additives | VANDERBILT CHEMICALS LLC (US) | 2018-11-15 | — | — | US | disclosed |
| US-10059901-B2 | Quaternary ammonium sulfur-containing binuclear molybdate salts as lubricant additives | VANDERBILT CHEMICALS, LLC (US) | 2018-08-28 | — | — | US | disclosed |
| WO-2017146939-A1 | QUATERNARY AMMONIUM SULFUR-CONTAINING BINUCLEAR MOLYBDATE SALTS AS LUBRICANT ADDITIVES | VANDERBILT CHEMICALS, LLC (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170240838-A1 | QUATERNARY AMMONIUM SULFUR-CONTAINING BINUCLEAR MOLYBDATE SALTS AS LUBRICANT ADDITIVES | VANDERBILT CHEMICALS, LLC (US) | 2017-08-24 | — | — | US | disclosed |
| WO-2007079252-A2 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS | AMPHASTAR PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-5955584-A | NON-PROTEIN ANTIGEN COMPOSED OF STEROID COMPONENT WITH 3 BETA HYDROXY OR 3 KETO GROUP AND QUATERNARY AMMONIUM SALT; FOR THERAPY AND IMMUNOASSAY DIAGNOSIS | CHARTER VENTURES (US) | 1999-09-21 | — | — | US | disclosed |
| US-5811248-A | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof | CHARTER VENTURES (US) | 1998-09-22 | — | — | US | disclosed |
| EP-0707489-A4 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS INC (US) | 1998-07-29 | — | — | EP | disclosed |
| EP-0707489-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | Scotgen Biopharmaceuticals, Inc. (US) | 1996-04-24 | — | — | EP | disclosed |
| WO-1994025053-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS, INC. (US) | 1994-11-10 | — | — | WO | disclosed |
| EP-0206947-B1 | PHARMACEUTICAL COMPOSITION CONTAINING CHOLINE ESTER SALTS FOR ENHANCING GASTROINTESTINAL TRACT ABSORPTION | MERCK & CO. INC. (US) | 1992-04-15 | — | — | EP | disclosed |
| EP-0214898-B1 | CHOLINE ESTERS AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL CAVITIES | MERCK & CO. INC. (US) | 1992-03-11 | — | — | EP | disclosed |
| US-4973579-A | VIRICIDES | MERCK & CO., INC. (US) | 1990-11-27 | — | — | US | disclosed |
| US-4963556-A | ANTIVIRAL AGENTS | MERCK & CO., INC. (US) | 1990-10-16 | — | — | US | disclosed |
| US-4835138-A | Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities | MERCK & CO., INC. (US) | 1989-05-30 | — | — | US | disclosed |
| US-4822773-A | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts | MERCK & CO., INC. (US) | 1989-04-18 | — | — | US | disclosed |
| US-4729989-A | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts | MERCK & CO., INC. (US) | 1988-03-08 | — | — | US | disclosed |
| US-4692441-A | B-LACTAM ANTIBIOTICS | MERCK & CO., INC. (US) | 1987-09-08 | — | — | US | disclosed |
| EP-0214898-A2 | Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities | MERCK & CO. INC. (US) | 1987-03-18 | — | — | EP | disclosed |
| EP-0206947-A2 | Pharmaceutical composition containing choline ester salts for enhancing gastrointestinal tract absorption | MERCK & CO. INC. (US) | 1986-12-30 | — | — | EP | disclosed |
| EP-0206947-A2 | Pharmaceutical composition containing choline ester salts for enhancing gastrointestinal tract absorption | MERCK & CO. INC. (US) | 1986-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | CYP27A1, LIPC, CYP46A1 | CES2 464/4885MAPK1 3368/4885CYP1A2 504/4885 |
| US-10590364-B2 | Quaternary ammonium sulfur-containing binuclear molybdate salts as lubricant additives | ATXN10, MDM4, OR10J3 | CES2 4694/4885MAPK1 1883/4885CYP1A2 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.